


Supporting Information

Rosmarinic acid-loaded polymeric nanoparticles prepared by low-energy nano-emulsion templating: formulation, biophysical characterisation, and *in vitro* studies


Jessica García-Melero, Joan-Josep López-Mitjavila, María José García-Celma, Carlos Rodríguez-Abreu and Santiago Grijalvo

CONTENT

Figure S1. Chemical structure of Rosmarinic acid (RA) and RA-loaded PLGA NPs	2
Table S1. HPLC conditions	2
Figure S2. DLS size distribution of unloaded PLGA NPs	3
Figure S3. DLS size distributions of RA-loaded PLGA NPs.	3
Figure S4. Dark-field microscopy studies	4
Figure S5. Calibration curve of RA	5
Figure S6. Fitted curve release kinetic models	5
Table S2. Drug release parameters	6
Figure S7. PLGA_PC images	6
Figure S8. DLS size distributions of PLGA_PC and RA-loaded PLGA_PC	7
Figure S9. Calibration curve of a model protein	7
Figure S10. PLGA NPs images in the absence of 10%FBS	8
Figure S11. <i>In vitro</i> scavenging effect of free RA and EC ₅₀ estimation	8
Figure S12. DLS size distribution of fluorescently labelled polymeric NPs	9

A

▲ Rosmarinic acid (RA)

B

RA-loaded PLGA polymeric nanoparticles



PLGA polymeric matrix

Figure S1. A. Chemical structure of Rosmarinic acid (RA); B. Representation of RA-loaded polymeric nanoparticles (NPs) used in this article

Table S1. Gradient elution conditions used to analyze RA elution by HPLC with a flow rate of 1 mL·min⁻¹.

Time (min)	%Water (A)	%Acetonitrile (B)
0	100	0
5	90	10
10	70	30
15	50	50
16	0	100
18	50	50
20	100	0




Figure S2. DLS size distribution of unloaded PLGA NPs




Figure S3. DLS size distributions of RA-loaded PLGA NPs prepared from ethyl acetate (A) and a mixture of ethyl acetate and ethanol in a ratio of 90:10 (B), respectively.

Dark-field microscopy images (100X) Dark-field hyperspectral microscopy images (100X)




Figure S4. A. Dark-field and dark-field hyperspectral microscopy images of PLGA NPs and RA; B. Scattering spectra (normalized to the lamp spectrum) of a selected region of PLGA NPs and RA (see insert)




Figure S5. HPLC calibration curve for RA




Figure S6. Fitted curves for RA release experimental data using (A) zero-order; (B) first-order; (C) Korsmeyer-Peppas, and (D) Higuchi equation kinetic models. For D, data were fitted for the 60% of the drug release from the nanoparticles.

Table S2. Drug release parameters for RA-loaded PLGA NPs according to zero-order, first-order, Korsmeyer, and Higuchi equation models

Zero-order		First-order		Korsmeyer-Peppas			Higuchi	
$\frac{M_t}{M_\infty} = Q_0 \times K_0 \times t$		$\frac{M_t}{M_\infty} = 100 \times (1 - e^{-K \cdot t})$		$\frac{M_t}{M_\infty} = K_{K-P} \times t^n$			$\frac{M_t}{M_\infty} = K_H \times \sqrt{t}$	
K_0	r^2	K	r^2	K_{K-P}	n	r^2	K_H	r^2
0.52	0.799	0.021	0.992	9.24	0.48	0.982*	7.40	0.965




Figure S7. Visual aspect of PLGA_PC NPs (non-loaded and RA-loaded) at two incubation times (1 and 5 hours) at 37 °C and 10% FBS.




Figure S8. DLS size distributions of PLGA_PC (A, B) and RA-loaded PLGA_PC (C, D) after 1 (A, C) and 5-hour (B, D) incubation. PC NPs were isolated by ultracentrifugation and resuspended in 2 mL of 1X PBS




Figure S9. Calibration curve using a model protein (BSA) at different concentrations ranging from 100 to 800 $\mu\text{g}\cdot\text{mL}^{-1}$. The equation $Y=0.0019x+0.0948$ was used to quantify the protein corona concentration adsorbed onto the surface of PLGA NPs




Figure S10 Visual aspect of PLGA NPs (non-loaded and RA-loaded) at two incubation times (1 and 5 hours) at 37 °C in the absence of 10% FBS.




Figure S11. *In vitro* scavenging effect of free RA using DPPH \cdot assay (A) and EC₅₀ estimation calculated from a regression line equation (B)




Figure S12. DLS size distribution of fluorescently labelled polymeric NPs containing coumarin-6